{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-112930","form_type":"8-K","ticker":"AKTX","cik":"0001541157","company_name":"Akari Therapeutics Plc","filed_at":"2024-10-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.747642+00:00","generated_at":"2026-05-30T20:02:49.341235+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Akari Therapeutics receives Nasdaq delisting notice; plans to appeal","bullets":["Received Nasdaq delisting determination on Oct 1, 2024 for non-compliance with $2.5M stockholders' equity requirement.","Company intends to request hearing by Oct 8, 2024; hearing automatically stays suspension.","Expects to regain compliance upon closing pending merger with Peak Bio, Inc.","No assurance of success; shares at risk of suspension if appeal fails."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-112930","json":"https://secwatch.observer/filing/0000950170-24-112930.json","markdown":"https://secwatch.observer/filing/0000950170-24-112930.md","text":"https://secwatch.observer/filing/0000950170-24-112930.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1541157/000095017024112930/0000950170-24-112930-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1541157/000095017024112930/aktx-20241001.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T20:02:49.341235+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}